KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Leases (2019 - 2025)

Sarepta Therapeutics (SRPT) has 8 years of Leases data on record, last reported at $139.2 million in Q3 2025.

  • For Q3 2025, Leases fell 1.23% year-over-year to $139.2 million; the TTM value through Sep 2025 reached $139.2 million, down 1.23%, while the annual FY2024 figure was $148.3 million, 14.13% up from the prior year.
  • Leases reached $139.2 million in Q3 2025 per SRPT's latest filing, down from $143.0 million in the prior quarter.
  • Across five years, Leases topped out at $148.3 million in Q4 2024 and bottomed at $43.0 million in Q3 2022.
  • Average Leases over 5 years is $99.3 million, with a median of $124.0 million recorded in 2024.
  • Peak YoY movement for Leases: tumbled 50.38% in 2021, then surged 210.11% in 2023.
  • A 5-year view of Leases shows it stood at $45.5 million in 2021, then skyrocketed by 42.66% to $65.0 million in 2022, then soared by 100.07% to $130.0 million in 2023, then increased by 14.13% to $148.3 million in 2024, then decreased by 6.16% to $139.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $139.2 million in Q3 2025, $143.0 million in Q2 2025, and $147.1 million in Q1 2025.